-
1
-
-
84875465140
-
The epidemiology of depression across cultures
-
Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013; 34: 119-138.
-
(2013)
Annu Rev Public Health
, vol.34
, pp. 119-138
-
-
Kessler, R.C.1
Bromet, E.J.2
-
2
-
-
0037831023
-
The epidemiology of major depressive disorder: Results from the national comorbidity survey replication (NCS-R)
-
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA. 2003; 289(23): 3095-3105.
-
(2003)
JAMA
, vol.289
, Issue.23
, pp. 3095-3105
-
-
Kessler, R.C.1
Berglund, P.2
Demler, O.3
-
3
-
-
33846050551
-
Prevalence of psychiatric disorders across Latino subgroups in the United States
-
Alegria M, Mulvaney-Day N, Torres M, Polo A, Cao Z, Canino G. Prevalence of psychiatric disorders across Latino subgroups in the United States. Am J Public Health. 2007; 97(1): 68-75.
-
(2007)
Am J Public Health
, vol.97
, Issue.1
, pp. 68-75
-
-
Alegria, M.1
Mulvaney-Day, N.2
Torres, M.3
Polo, A.4
Cao, Z.5
Canino, G.6
-
4
-
-
80555142935
-
Major depressive disorder in the African American population
-
Bailey RK, Patel M, Barker NC, Ali S, Jabeen S. Major depressive disorder in the African American population. J Natl Med Assoc. 2011; 103(7): 548-557.
-
(2011)
J Natl Med Assoc
, vol.103
, Issue.7
, pp. 548-557
-
-
Bailey, R.K.1
Patel, M.2
Barker, N.C.3
Ali, S.4
Jabeen, S.5
-
5
-
-
76649118757
-
The associations between socio-economic status and major depressive disorder among blacks, Latinos, Asians and non-Hispanic whites: Findings from the collaborative psychiatric epidemiology studies
-
Gavin AR, Walton E, Chae DH, Alegria M, Jackson JS, Takeuchi D. The associations between socio-economic status and major depressive disorder among blacks, Latinos, Asians and non-Hispanic whites: findings from the collaborative psychiatric epidemiology studies. Psychol Med. 2010; 40(1): 51-61.
-
(2010)
Psychol Med
, vol.40
, Issue.1
, pp. 51-61
-
-
Gavin, A.R.1
Walton, E.2
Chae, D.H.3
Alegria, M.4
Jackson, J.S.5
Takeuchi, D.6
-
6
-
-
35748945434
-
Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's world mental health survey initiative
-
Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's world mental health survey initiative. World Psychiatry. 2007; 6 (3): 168-176.
-
(2007)
World Psychiatry
, vol.6
, Issue.3
, pp. 168-176
-
-
Kessler, R.C.1
Angermeyer, M.2
Anthony, J.C.3
-
7
-
-
79960659664
-
Cross-national epidemiology of DSM-IV major depressive episode
-
Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011; 9: 90.
-
(2011)
BMC Med
, vol.9
, pp. 90
-
-
Bromet, E.1
Andrade, L.H.2
Hwang, I.3
-
8
-
-
71649092235
-
Health related quality of life in recurrent depression: A comparison with a general population sample
-
ten Doesschate MC, Koeter MW, Bockting CL, Schene AH. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2010; 120(1-3): 126-132.
-
(2010)
J Affect Disord
, vol.120
, Issue.1-3
, pp. 126-132
-
-
Ten Doesschate, M.C.1
Koeter, M.W.2
Bockting, C.L.3
Schene, A.H.4
-
9
-
-
30044433660
-
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: Implications for clinical practice
-
Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry. 2006; 163(1): 28-40.
-
(2006)
Am J Psychiatry
, vol.163
, Issue.1
, pp. 28-40
-
-
Trivedi, M.H.1
Rush, A.J.2
Wisniewski, S.R.3
-
10
-
-
77952371046
-
Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder
-
Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol. 2010; 30(3): 294-299.
-
(2010)
J Clin Psychopharmacol
, vol.30
, Issue.3
, pp. 294-299
-
-
Kornstein, S.G.1
Clayton, A.H.2
Soares, C.N.3
Padmanabhan, S.K.4
Guico-Pabia, C.J.5
-
11
-
-
84855946303
-
The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder
-
Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin. 2012; 28(1): 27-39.
-
(2012)
Curr Med Res Opin
, vol.28
, Issue.1
, pp. 27-39
-
-
Reed, C.R.1
Kajdasz, D.K.2
Whalen, H.3
Athanasiou, M.C.4
Gallipoli, S.5
Thase, M.E.6
-
12
-
-
79551586265
-
Examining the role of race and ethnicity in relapse rates of major depressive disorder
-
Trinh NH, Shyu I, McGrath PJ, et al. Examining the role of race and ethnicity in relapse rates of major depressive disorder. Compr Psychiatry. 2011; 52(2): 151-155.
-
(2011)
Compr Psychiatry
, vol.52
, Issue.2
, pp. 151-155
-
-
Trinh, N.H.1
Shyu, I.2
McGrath, P.J.3
-
13
-
-
84882847258
-
Treatment response for acute depression is not associated with number of previous episodes: Lack of evidence for a clinical staging model for major depressive disorder
-
Dodd S, Berk M, Kelin K, Mancini M, Schacht A. Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder. J Affect Disord. 2013; 150(2): 344-349.
-
(2013)
J Affect Disord
, vol.150
, Issue.2
, pp. 344-349
-
-
Dodd, S.1
Berk, M.2
Kelin, K.3
Mancini, M.4
Schacht, A.5
-
14
-
-
84860758903
-
Is prior course of illness relevant to acute or longer-term outcomes in depressed outpatients? A STAR∗D report
-
Rush AJ, Wisniewski SR, Zisook S, et al. Is prior course of illness relevant to acute or longer-term outcomes in depressed outpatients? A STAR∗D report. Psychol Med. 2012; 42(6): 1131-1149.
-
(2012)
Psychol Med
, vol.42
, Issue.6
, pp. 1131-1149
-
-
Rush, A.J.1
Wisniewski, S.R.2
Zisook, S.3
-
15
-
-
84875936452
-
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report
-
Sung SC, Wisniewski SR, Balasubramani GK, et al. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychol Med. 2013; 43(5): 945-960.
-
(2013)
Psychol Med
, vol.43
, Issue.5
, pp. 945-960
-
-
Sung, S.C.1
Wisniewski, S.R.2
Balasubramani, G.K.3
-
16
-
-
57049148576
-
Factors predicting reduced antidepressant response: Experience with the SNRI duloxetine in patients with major depression
-
Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry. 2008; 20(4): 209-218.
-
(2008)
Ann Clin Psychiatry
, vol.20
, Issue.4
, pp. 209-218
-
-
Howland, R.H.1
Wilson, M.G.2
Kornstein, S.G.3
-
17
-
-
34447321014
-
Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression
-
Shelton RC, Prakash A, Mallinckrodt CH, et al. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract. 2007; 61(8): 1337-1348.
-
(2007)
Int J Clin Pract
, vol.61
, Issue.8
, pp. 1337-1348
-
-
Shelton, R.C.1
Prakash, A.2
Mallinckrodt, C.H.3
-
18
-
-
59049084835
-
Objective: Remission of depression in primary care: The OREON Study
-
Ansseau M, Demyttenaere K, Heyrman J, Migeotte A, Leyman S, Mignon A. Objective: remission of depression in primary care: the OREON Study. Eur Neuropsychopharmacol. 2009; 19(3): 169-176.
-
(2009)
Eur Neuropsychopharmacol
, vol.19
, Issue.3
, pp. 169-176
-
-
Ansseau, M.1
Demyttenaere, K.2
Heyrman, J.3
Migeotte, A.4
Leyman, S.5
Mignon, A.6
-
19
-
-
84555194678
-
Efficacy of antidepressants for late-life depression: A meta-analysis and meta-regression of placebo-controlled randomized trials
-
Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011; 72(12): 1660-1668.
-
(2011)
J Clin Psychiatry
, vol.72
, Issue.12
, pp. 1660-1668
-
-
Tedeschini, E.1
Levkovitz, Y.2
Iovieno, N.3
Ameral, V.E.4
Nelson, J.C.5
Papakostas, G.I.6
-
20
-
-
77952569120
-
Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder
-
Okuda A, Suzuki T, Kishi T, et al. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci. 2010; 64(3): 268-273.
-
(2010)
Psychiatry Clin Neurosci
, vol.64
, Issue.3
, pp. 268-273
-
-
Okuda, A.1
Suzuki, T.2
Kishi, T.3
-
21
-
-
3042517258
-
One-year clinical outcomes of depressed public sector outpatients: A benchmark for subsequent studies
-
Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry. 2004; 56 (1): 46-53.
-
(2004)
Biol Psychiatry
, vol.56
, Issue.1
, pp. 46-53
-
-
Rush, A.J.1
Trivedi, M.2
Carmody, T.J.3
-
22
-
-
84893016429
-
-
New York: Forest Laboratories, Inc.
-
Fetzima [prescribing information]. New York: Forest Laboratories, Inc.; 2013.
-
(2013)
Fetzima [Prescribing Information]
-
-
-
23
-
-
84995361691
-
-
New York: Forest Laboratories, Inc.
-
Savella [prescribing information]. New York: Forest Laboratories, Inc.; 2013.
-
(2013)
Savella [Prescribing Information]
-
-
-
24
-
-
84876993979
-
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety
-
Auclair AL, Martel JC, Assie MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013; 70: 338-347.
-
(2013)
Neuropharmacology
, vol.70
, pp. 338-347
-
-
Auclair, A.L.1
Martel, J.C.2
Assie, M.B.3
-
25
-
-
84875475046
-
The efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: A phase 3, randomized, double-blind, placebo-controlled study
-
Asnis G, Bose A, Gommoll C, Chen C, Greenberg WM. The efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013; 74(3): 242-248.
-
(2013)
J Clin Psychiatry
, vol.74
, Issue.3
, pp. 242-248
-
-
Asnis, G.1
Bose, A.2
Gommoll, C.3
Chen, C.4
Greenberg, W.M.5
-
26
-
-
84891816383
-
Levomilnacipran ER 40mg and 80mg in patients with major depressive disorder: A phase III, randomized, double-blind, fixed-dose, placebo-controlled study
-
Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40mg and 80mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014; 39(1): 40-49.
-
(2014)
J Psychiatry Neurosci
, vol.39
, Issue.1
, pp. 40-49
-
-
Bakish, D.1
Bose, A.2
Gommoll, C.3
-
27
-
-
84895860088
-
A randomized double-blind, placebo-controlled, study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder
-
Gommoll C, Greenberg WM, Chen C. A randomized double-blind, placebo-controlled, study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. Journal of Drug Assessment. 2014; 3: 10-19.
-
(2014)
Journal of Drug Assessment
, vol.3
, pp. 10-19
-
-
Gommoll, C.1
Greenberg, W.M.2
Chen, C.3
-
28
-
-
84891737410
-
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder
-
Sambunaris A, Bose A, Gommoll C, et al. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014; 34(1): 47-56.
-
(2014)
J Clin Psychopharmacol
, vol.34
, Issue.1
, pp. 47-56
-
-
Sambunaris, A.1
Bose, A.2
Gommoll, C.3
-
29
-
-
84876570587
-
The efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: A randomized, double-blind, placebo-controlled, proof-of-concept study
-
Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D. The efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013; 74(4): 363-369.
-
(2013)
J Clin Psychiatry
, vol.74
, Issue.4
, pp. 363-369
-
-
Montgomery, S.A.1
Mansuy, L.2
Ruth, A.3
Bose, A.4
Li, H.5
Li, D.6
-
31
-
-
67649206008
-
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
-
Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009; 24(3): 111-118.
-
(2009)
Int Clin Psychopharmacol
, vol.24
, Issue.3
, pp. 111-118
-
-
Montgomery, S.A.1
Moller, H.J.2
-
32
-
-
3142554206
-
Implications of using different cut-offs on symptom severity scales to define remission from depression
-
Zimmerman M, Posternak MA, Chelminski I. Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol. 2004; 19(4): 215-220.
-
(2004)
Int Clin Psychopharmacol
, vol.19
, Issue.4
, pp. 215-220
-
-
Zimmerman, M.1
Posternak, M.A.2
Chelminski, I.3
-
33
-
-
41549125307
-
Sex differences in depression symptoms in treatment-seeking adults: Confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study
-
Marcus SM, Kerber KB, Rush AJ, et al. Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Compr Psychiatry. 2008; 49(3): 238-246.
-
(2008)
Compr Psychiatry
, vol.49
, Issue.3
, pp. 238-246
-
-
Marcus, S.M.1
Kerber, K.B.2
Rush, A.J.3
-
34
-
-
50349087007
-
Efficacy of second generation antidepressants in late-life depression: A meta-analysis of the evidence
-
Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008; 16(7): 558-567.
-
(2008)
Am J Geriatr Psychiatry
, vol.16
, Issue.7
, pp. 558-567
-
-
Nelson, J.C.1
Delucchi, K.2
Schneider, L.S.3
-
35
-
-
19244374612
-
Differentiating moderate and severe depression using the Montgomery-Asberg Depression Rating Scale (MADRS)
-
Müller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg Depression Rating Scale (MADRS). J Affect Disord. 2003; 77(3): 255-260.
-
(2003)
J Affect Disord
, vol.77
, Issue.3
, pp. 255-260
-
-
Müller, M.J.1
Himmerich, H.2
Kienzle, B.3
Szegedi, A.4
-
36
-
-
57049188862
-
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD
-
Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009; 19(1): 34-40.
-
(2009)
Eur Neuropsychopharmacol
, vol.19
, Issue.1
, pp. 34-40
-
-
Papakostas, G.I.1
Fava, M.2
|